AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.

Bydureon is a medication that contains the active ingredient exenatide, which is a synthetic version of a hormone called GLP-1 (glucagon-like peptide-1). there are countless points of light in the ...

At present, streaming OTT box/sticks & shrewd TVs are the two most normal gadget types for streaming. However, inside every one of these gadget classifications is a few brands battling for a portion ...